Robert F. Kennedy Jr. has stepped in to defend President Trump's assertions about prescription drug discounts, even as the numbers the president is touting exceed what's mathematically possible.
Trump has claimed to have secured discounts ranging from 400 to 1,500 percent on prescription drugs. The problem is elementary: a discount cannot exceed 100 percent, since doing so would drive the price below zero, which is impossible.
Kennedy, who leads the administration's health initiatives, has not publicly walked back the figures. Instead, he's moved forward with messaging around drug cost reduction as a centerpiece of the current healthcare agenda.
The discrepancy raises questions about how the administration plans to communicate its prescription drug strategy to the public. While bringing down medication costs is a stated priority, the framing of the achievement has created confusion about what exactly has been accomplished and what the metrics actually represent.
Supporters have suggested the president may be describing the value of the savings in different terms, or that there's a communication gap between what was promised and what was delivered. Critics, however, view the inflated figures as misleading marketing of a policy initiative.
The episode underscores a broader tension in the administration between making bold claims about results and the practical mechanics of pharmaceutical pricing. Whether the actual drug discounts, if implemented, will be substantial enough to satisfy the public's expectations remains to be seen.
Author Sarah Mitchell: "When the nation's health leaders are defending statements that defy basic math, you've got a credibility problem that no spin can fix."
Comments